US regulatory status: approved.
pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria
Alexion Europe SAS
Alexion Europe SAS drug portfolio — 40 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
89 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Employees
- 89
- Programs
- 33
- Drugs
- 40
- Patents
- 0
Alexion Europe SAS pipeline
Portfolio lens on 40 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alexion Europe SAS drug portfolio — 40 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
asfotase alfa
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Pyrophosphate.
- Target
- Pyrophosphate
- Mechanism
- Pyrophosphate hydrolytic enzyme
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
danicopan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement factor D.
- Target
- Complement factor D
- Mechanism
- Complement factor D inhibitor
-
eculizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
human igg1 monoclonal antibody specific for human interleukin-1 alpha
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Alexion Europe SAS's portfolio.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Alexion Europe SAS in public FDA and regional records. Mechanism: Somatostatin receptor 2 agonist.
- Mechanism
- Somatostatin receptor 2 agonist
-
US regulatory status: approved. Molecular target: Somatostatin receptor type 2.
- Target
- Somatostatin receptor type 2
- Mechanism
- Somatostatin receptor 5 agonist
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
octreotide
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Alexion Europe SAS's portfolio. Mechanism: Somatostatin receptor agonist.
- Mechanism
- Somatostatin receptor agonist
-
US regulatory status: approved. Molecular target: Somatostatin receptor.
- Target
- Somatostatin receptor
- Mechanism
- Somatostatin receptor agonist
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
ravulizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Alexion Europe SAS's portfolio. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
sirolimus
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
US regulatory status: approved.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
Development asset linked to Alexion Europe SAS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist